肾素-血管紧张素-醛固酮系统抑制剂与Covid-19风险
该研究评估既往使用ACE抑制剂、血管紧张素受体阻滞剂、β受体阻滞剂、钙通道阻滞剂或噻嗪类利尿剂与Covid-19检测阳性或阴性结果的可能性,以及检测阳性患者重症(定义为重症监护、机械通气或死亡)可能性的关系。采用贝叶斯方法,在倾向评分匹配后比较使用与未使用这些药物的患者,总体及高血压患者中。在12594例检测患者中,5894例(46.8%)阳性,其中1002例(17.0%)重症。未发现任何单类药物与检测阳性可能性增加相关,也未发现与检测阳性患者重症风险实质性增加相关。
要点
- 在12594例Covid-19检测患者中,5894例(46.8%)阳性,1002例(17.0%)为重症。
- 既往使用ACE抑制剂、ARB、β受体阻滞剂、钙通道阻滞剂或噻嗪类利尿剂与检测阳性可能性增加无关。
- 检测阳性患者中,上述五类降压药均未与重症风险实质性增加相关。
- 高血压患者4357例(34.6%),其中2573例(59.1%)检测阳性,634例(24.6%)重症。
- 预设至少10个百分点的差异为实质性差异。
适用人群与场景
- 接受Covid-19检测的患者,共12594例。
- 高血压患者4357例(34.6%)。
诊断标准与关键阈值
- 重症定义为重症监护、机械通气或死亡。
研究设计与关键结果
- 研究采用贝叶斯方法,在倾向评分匹配后比较使用与未使用ACE抑制剂、血管紧张素受体阻滞剂、β受体阻滞剂、钙通道阻滞剂或噻嗪类利尿剂的患者,总体及高血压患者中。
- 12594例检测患者中5894例(46.8%)阳性,其中1002例(17.0%)重症。
- 高血压患者4357例(34.6%),其中2573例(59.1%)检测阳性,634例(24.6%)重症。
- 未发现任何单类药物与检测阳性可能性增加相关。
- 检测阳性患者中,所研究的药物均未与重症风险实质性增加相关。
证据类型、等级与局限
- 证据类型:观察性研究,采用贝叶斯方法和倾向评分匹配。
- 预设至少10个百分点的差异为实质性差异。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文结论:五种常见降压药与Covid-19检测阳性或检测阳性患者重症风险实质性增加无关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: There is concern about the potential of an increased risk related to medications that act on the renin-angiotensin-aldosterone system in patients exposed to coronavirus disease 2019 (Covid-19), because the viral receptor is angiotensin-converting enzyme 2 (ACE2).
METHODS: We assessed the relation between previous treatment with ACE inhibitors, angiotensin-receptor blockers, beta-blockers, calcium-channel blockers, or thiazide diuretics and the likelihood of a positive or negative result on Covid-19 testing as well as the likelihood of severe illness (defined as intensive care, mechanical ventilation, or death) among patients who tested positive. Using Bayesian methods, we compared outcomes in patients who had been treated with these medications and in untreated patients, overall and in those with hypertension, after propensity-score matching for receipt of each medication class. A difference of at least 10 percentage points was prespecified as a substantial difference.
RESULTS: Among 12,594 patients who were tested for Covid-19, a total of 5894 (46.8%) were positive; 1002 of these patients (17.0%) had severe illness. A history of hypertension was present in 4357 patients (34.6%), among whom 2573 (59.1%) had a positive test; 634 of these patients (24.6%) had severe illness. There was no association between any single medication class and an increased likelihood of a positive test. None of the medications examined was associated with a substantial increase in the risk of severe illness among patients who tested positive.
CONCLUSIONS: We found no substantial increase in the likelihood of a positive test for Covid-19 or in the risk of severe Covid-19 among patients who tested positive in association with five common classes of antihypertensive medications.
参考来源
- Reynolds HR, Adhikari S, Pulgarin C, et al. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19. N Engl J Med. 2020. PMID: 32356628. doi:10.1056/NEJMoa2008975
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。